In December, Tehrani signed a deal with GlaxoSmithKline that will allow the pharmaceutical giant to test at least four of its drug candidates on a Zymeworks -
designed platform, which combines a computer simulation with a way of engineering protein molecules and allows products to be
refined before they move to expensive
clinical trials.